Showing 21 - 30 of 48,511
Objective: To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in persons with AIDS. Design: Incidence-based simulation model of CMV treatment from a government payer perspective. Setting: Swiss healthcare system. Patients and participants:...
Persistent link: https://www.econbiz.de/10005243151
Treatment of adult chickenpox with aciclovir is controversial because of the relatively high cost of medication and small proven benefits of therapy. A decision-tree model was used to estimate the cost effectiveness of aciclovir, from third-party payer and societal perspectives: the incremental...
Persistent link: https://www.econbiz.de/10005243155
Background: Zanamivir, a neuraminidase inhibitor, reduces the number of days of illness in influenza-positive patients. New bedside rapid flu tests (RFT) should increase the number of influenza-positive patients whom receive zanamivir appropriately. Objective: To estimate the economic effects of...
Persistent link: https://www.econbiz.de/10005243184
Hepatitis C is an important target for the development of disease management programs. Hepatitis C virus (HCV) infection is common and most infected individuals develop persistent infection. Although this is usually associated with chronic liver injury (chronic hepatitis C), the infection and...
Persistent link: https://www.econbiz.de/10005448791
Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...
Persistent link: https://www.econbiz.de/10005448902
The notable increase in the quantity of economic evaluations in the last 2 decades has not been matched by good methodological standards. This problem is particularly evident in the field of economic evaluations of hepatitis B vaccines. The results of 2 systematic reviews conducted by us in 1993...
Persistent link: https://www.econbiz.de/10005448973
The purpose of this study is to determine drug costs and the sociodemographic and clinical determinants of drug costs in a large open cohort of HIV-positive adult men and women in British Columbia, Canada from 1993 to 1995. The study is descriptive and population-based using time-series data....
Persistent link: https://www.econbiz.de/10005448996
A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii)...
Persistent link: https://www.econbiz.de/10005449026
Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...
Persistent link: https://www.econbiz.de/10005449227
The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were...
Persistent link: https://www.econbiz.de/10005449286